Introduction
Lymphotoxin (LT) is expressed by activated lymphocytes in secreted and membrane forms (1) . Secreted LT is an LTα homotrimer (LTα3) which binds to the receptors TNF-R55 and TNF-R75, which are also the receptors for the soluble and membrane forms of tumor necrosis factor (TNF). Membrane LT consists of LTα anchored to the cell surface by association with LTβ, a type II membrane protein (1) . The heterotrimer exists predominantly in the LTα1β2 form, which binds a unique receptor termed LTβ-R (2) . Evidence that LT is involved in lymphoid organ genesis first came from studies of mice with a disrupted LTα gene (3, 4) . Although LTα-/-mice lack all lymph nodes (LN) and Peyer's patches, mice with genetic disruptions of TNF, TNF-R55 and TNF-R75 do not share this phenotype (5) (6) (7) (8) . These observations led to the hypothesis that the LTαβ ligand acts via LTβ-R to mediate the genesis of secondary lymphoid tissues (1, 3) . This postulate was confirmed by our initial report demonstrating that in utero their initial genesis, subsequent occupation and ultimate organization requires interactions between resident stromal cells and circulating cells such as lymphocytes. LN and Peyer's patches fail to develop in the Ikaros knockout mice which lack all lymphocytes (15) and remain poorly differentiated in SCID mice (16) . In normal mice, severing afferent lymphatics from LN causes down-regulation of addressin expression on high endothelial venules (HEV), possibly due to the loss of incoming cells (17, 18) . The thymus forms in Ikaros-/-mice but is atrophied (15) , while in α 4 integrin-/-chimeric mice, the thymus atrophies only after T cell migration becomes α 4 -dependent, showing that constant interaction between cell populations is required to maintain organization (19) . Disruption of the relB gene produces mice that lack dendritic cells and a thymic epithelial cell population (20, 21) . These mice do not form a thymic medulla, presumably because a critical signal involving epithelial cells fails to occur, and have disorganized splenic architecture with poorly differentiated T and B cell zones, which may be due to the lack of dendritic cells (20) . The mechanisms by which LT exerts its effect on LN genesis and splenic organization are not known.
In this study we evaluate the specific roles of LT and TNF ligands in the genesis and cellular organization of LN. These experiments identify a mucosal subset of LN which develop independently of membrane LTαβ signals, suggesting that multiple LTα-dependent pathways exist for LN genesis. We show that the pathways of LN genesis do not correlate with LN addressin phenotype. Moreover, functionally defined mucosal LN are shown to be heterogeneous with respect to addressin expression. Finally we report that membrane LTαβ and soluble LTα/TNF influence the formation of primary but not secondary B cell follicles in LN, results different from those derived from experiments on the spleen. Thus, antagonism of membrane LTαβ and soluble LTα/TNF has varying effects on GC formation in LN and spleen, suggesting that the requirements for GC formation may be distinct in different lymphoid organs. We conclude that multiple LT/TNF ligands are pivotal in organizing lymphocyte populations within lymphoid tissues.
Methods

Fusion proteins
Fusion proteins were prepared as described (9) . Briefly, the fusion proteins are comprised of the extracellular domain of either murine LTβ-R, human LFA-3 (which does not bind murine CD2) or human TNF-R55 (which binds murine TNF and murine LTα homotrimers) fused to the hinge, C H 2 and C H 3 domains of human IgG1.
Animals and treatment regimes
Timed pregnant BALB/c mice (Jackson Laboratories, Bar Harbor, ME) and LTα-deficient mice (3) were housed under conventional barrier protection, and handled in accordance with institutional guidelines. Injections during pregnancy were given into the tail vein (i.v.); dosing after birth was performed i.p. Timed pregnant mice were treated with 100 µg of fusion protein on gestational day 9 (LTβ-R-Ig) or 8 (TNF-R55-Ig or LFA-3-Ig) or with 200 µg of fusion protein on gestational days 14 and 17 followed by weekly dosing with 100 µg i.p. Mice were immunized with 250 µl 20% sheep red blood cells given i.p, then sacrificed 10 days later for analysis of the presence of peanut agglutinin (PNA)-reactive GC in the LN and spleen.
ELISA analysis and immunohistochemistry
Ig fusion protein levels in serum of treated animals were measured by ELISA as described previously (9) . Tissues were harvested into 20% sucrose/PBS for 30 min prior to freezing in OCT compound (Miles, Elkhart, IN). Frozen sections were prepared and incubated as described previously (9) . Sections were stained using the following mAb and detection reagents: binding of biotinylated anti-B220 mAb (10 µg/ml; PharMingen, San Diego, CA) was detected using 20 µg/ml streptavidinhorseradish peroxidase and tyramide-FITC, as directed by the manufacturer (NEN, Boston, MA). The use of the tyramide signal amplification system to deposit tyramide-FITC onto sites having peroxidase activity enhances the FITC signal without loss of resolution. Binding of the MAdCAM-1-specific mAb MECA367 (10 µg/ml; PharMingen), 1:5 dilution of mAb MOMA-1 cell culture supernatant (Serotec, Oxford, UK) or anti-sialoadhesin mAb (20 µg/ml; Serotec) was detected using 10 µg/ml FITC-or phycoerythrin (PE)-goat F(abЈ) 2 anti-rat IgG (Southern Biotechnology Associates, Birmingham, AL). Binding of mAb MECA79 (in culture supernatant) specific for peripheral LN addressin (ATCC, Rockville, MD) or 1:50 diluted mAb ER-TR-9 (Bachem Bioscience, King of Prussia, PA) was detected using 20 µg/ml FITC-or PE-mouse anti-rat IgM (PharMingen). Binding of biotinylated PNA (50 µg/ml; Vector Labs, Burlingame, CA) was detected using 10 µg/ml streptavidin-PE (Southern Biotechnology Associates). PE-rat antimouse CD4 (PharMingen) was used at 4 µg/ml. Some sections were stained with multiple mAb simultaneously to allow image overlay analysis. All sections were viewed under ϫ50 or ϫ100 optics and captured as digitized image files as described previously (9) . The images shown are representative of those obtained from a minimum of four animals per treatment group from a minimum of four independent experiments.
Results
Membrane LTαβ inhibition during development defines a novel subset of LN
Previously we reported that gestational blockade of membrane LTαβ disrupts development of secondary lymphoid organs (9) . Specifically, brachial, axillary, inguinal and popliteal LN were shown to be absent, although mesenteric LN were present in the progeny of mice treated with 200 µg of LTβ-RIg or anti-LTβ mAb on gestational days 13 and 17. We now show that the mandibular, parathymic, iliac and sciatic LN were also absent from 6-week-old progeny which had been treated in utero with LTβ-R-Ig (Table 1) . Neither residual LN anlage nor ectopic foci were detected at or near sites where such LN are normally located, as determined by India ink uptake from the circulation. Interestingly, in addition to having mesenteric LN, mice treated in utero with LTβ-R-Ig even as early as gestational day 9 also had cervical, sacral and lumbar LN ( Table 1 ). The location of some LN is represented The presence or absence of Peyer's patches and intestinal B cell follicles was determined visually using ϫ40 magnification and confirmed after fixing the intestines in 10% acetic acid. d The expression of addressins in LN is indicated by a 'ϩ' sign, the failure to express addressins in the LN is indicated by a '-' sign. A zero indicates that LN did not develop in that mice and thus LN addressin expression could not be evaluated. NR, not reported. in Fig. 1 . The most striking example of the selectivity of LTβ-R-Ig treatment on LN development was seen within the anatomically juxtaposed LN of the iliosacral group. Experiments showed that the sacral LN was present while the iliacs, which lie cranial to the aortic bifurcation, were absent in mice treated in utero with LTβ-R-Ig (Fig. 2) . We also confirm that all LN are absent from LTα-/-mice as previously reported (3, 4) and show that treatment with TNF-R55-Ig in utero fails to disrupt LN development (Table 1) .
Peyer's patches do not develop in mice treated in utero with LTβ-R-Ig (9). In contrast, gestational blockade of soluble LT/TNF with TNF-R55-Ig did not affect Peyer's patch genesis (9) . To ensure that the latter observation was not a result of insufficient levels of TNF-R55-Ig, pregnant mice were treated with 200 µg of TNF-R55-Ig on gestational days 14 and 17. Progeny so treated were born with an average of 10 µg/ml of TNF-R55-Ig in the circulation on the day of birth. Six pups from two different litters so treated were also injected with an additional 100 µg TNF-R55-Ig on the day after birth and then were dosed weekly with 100 µg TNF-R55-Ig. These mice were analyzed at 6 weeks of age, and found to have similar numbers of Peyer's patches of the same size and distribution as control mice. Thus LTβ-R-Ig but not TNF-R55-Ig treatment in utero and after birth disrupted the development of Peyer's patches, in contrast with a report detailing the absence of Peyer's patches in TNF-R55-/-mice (22) .
Blocking membrane LT, but not soluble LT/TNF, down-regulates addressin expression in LN
We considered that these two distinct LTα-dependent pathways of LN genesis might be related to the addressin phenotype of the different sets of LN identified. Addressins are expressed on HEV in the paracortical zone and cortex of LN. Immunohistochemical analysis of LN of normal adult mice showed that the HEV of sacral LN shared the same addressin phenotype as mesenteric LN, which also develop in LTβ-R-Ig-treated mice. The HEV of sacral and mesenteric LN expressed epitopes which reacted with MECA367 only, with both MECA367 and MECA79, and with MECA79 only, showing that both MAdCAM-1 and peripheral node addressins (PNAd) were expressed on the HEV of these LN (Fig. 3A-D) . This addressin phenotype is also identical to that of the Peyer's patches which do not develop in LTβ-R-Ig-treated mice. Lumbar and cervical LN, which also develop in mice treated gestationally with LTβ-R-Ig, reacted with MECA79 only (Fig.  3E and F, and data not shown). This peripheral addressin phenotype is shared with the mandibular, inguinal, iliac, popliteal and other LN which fail to develop in mice treated gestationally with LTβ-R-Ig. We conclude that the set of LN identified as sharing a unique, membrane LTαβ-independent developmental pathway cannot be discriminated on the basis of their addressin phenotype in adult mice. Moreover, as cervical, mesenteric, lumbar and sacral LN all drain mucosal surfaces (23), we have shown that functionally defined mucosal LN are not homogeneous with respect to addressin expression.
MAdCAM-1 is expressed early in the development of all LN (24) . As we previously noted that splenic MAdCAM-1 expression is modulated in vivo by LTβ-R-Ig treatment (9), we next assessed whether LN addressin expression was altered in 6-week-old mice which had been treated with 200 µg of LTβ-R-Ig in utero on gestational days 14 and 17, and weekly after birth with 100 µg of LTβ-R-Ig. Immunohistochemical staining with MECA367 and MECA79 showed that MAdCAM-1 and PNAd were not expressed in mesenteric and sacral LN of mice so treated with LTβ-R-Ig (Fig. 4E and data not shown). The cervical and iliac LN from these mice also failed to express PNAd (data not shown). In addition, the brachial LN, which develops prior to gestational day 14 and is therefore not eliminated in the progeny of mice treated with LTβ-R-Ig on gestational day 14 or later (9), also lacked PNAd staining (Fig. 4F ). Thus treatment with LTβ-R-Ig affects addressin expression in LN which are dependent on or independent of membrane LTαβ for their genesis. The downregulation of MAdCAM-1 expression was also noted in the mesenteric LN of newborn mice which had been treated only in utero with LTβ-R-Ig (data not shown). Addressin modulation by soluble receptor treatment was reversible, as LN addressin levels of 6-week-old mice which were treated only in utero with LTβ-R-Ig were similar to levels seen in control animals ( Fig. 4G and H) . Finally, the effects of LTβ-R-Ig on LN addressin expression were specific as the LN of mice treated in utero and throughout life with 100 µg/week of TNF-R55-Ig or LFA-3-Ig had addressin expression comparable to that detected in LN of untreated, age-and sex-matched, control mice (Fig. 4A-D and Table 1 ).
The role of membrane LTαβ and soluble LTα/TNF in cellular organization of LN
As addressin down-regulation would be expected to influence LN cellularity (25) and since disruption of LT ligands has marked effects on cellular organization in the spleen (3,5,9-13,26), we examined the effects of soluble LTα/TNF and membrane LTαβ blockade on cell populations in LN. First markers expressed by macrophage populations in the LN subcapsular sinus were examined by immunohistochemistry. Mesenteric LN taken from 6-week-old mice which had been treated in utero on gestational days 14 and 17 with 200 µg and weekly after birth with 100 µg of LTβ-R-Ig, TNF-R55-Ig or LFA-3-Ig were assessed by immunohistochemistry using mAb which recognize sialoadhesin or the MOMA-1 antigen. Sialoadhesin expression by metallophilic macrophages in the mesenteric LN subcapsular sinus was reduced in LTβ-R-Ig-treated mice (Fig. 5D ), but not in mesenteric LN of TNF-R55-Ig-or LFA-3-Ig-treated mice (Fig. 5 B and F) . MOMA-1 ligand expression on macrophages in the subcapsular sinus was also diminished by LTβ-R-Ig treatment (data not shown). Identical results were obtained from examination of cervical, sacral, lumbar and brachial LN from LTβ-R-Ig-treated mice.
Although the functional significance of sialoadhesin expression on cells in the LN subcapsular sinus is not understood, there is a correlation of the down-regulation of sialoadhesin and other marginal zone markers with lymphocyte positioning in the spleen of LTβ-R-Ig-treated mice (A and B) , sacral (C and D) and cervical (E and F) LN were dissected from adult mice. LN sections were stained with mAb MECA79 (A, C and E) or MECA367 (B, D and F), specific for PNAd and MAdCAM-1 respectively. Magnification ϫ100. (9, 11, 26) . We therefore evaluated the status of lymphocyte organization in the LN present in LTβ-R-Ig-treated mice. Frozen sections of LN taken from 6-week-old mice treated on gestational days 14 and 17 with 200 µg of LTβ-R-Ig and weekly after birth with 100 µg of LTβ-R-Ig were stained with mAb specific for the B cell marker B220 and the T cell marker CD4. Such LTβ-R-Ig treatment resulted in the dissolution of B cell follicles such that B cells were present in a diffuse band on the outer margin of the T cell area (Fig. 5C) . B cells were not present within T cell areas of the LN, but rather were detected in areas of the subcapsular sinus not normally occupied by lymphocytes. This distinctive pattern of B cell staining was observed in the mesenteric, sacral and cervical LN of mice treated with LTβ-R-Ig, as well as in the brachial LN which developed in mice treated late during gestation with LTβ-R-Ig (data not shown). A very similar pattern of T and B cell staining was observed in all LN of mice treated in utero and throughout life with 100 µg/week TNF-R55-Ig (Fig. 5E ), but not LFA-3-Ig (Fig. 5A and data not shown) . Thus both LTβ-R-Ig and TNF-R55-Ig treatments change lymphocyte positioning in LN, whereas only the former influences the expression of functional markers on metallophilic macrophages. These results show that neither the expression of addressins on HEV nor of functional markers on LN subcapsular sinus macrophages is sufficient to organize lymphocyte populations in LN.
The role of membrane LTαβ and soluble LTα/TNF in cellular organization of spleen
As soluble LTα/TNF and membrane LTαβ mediated distinct effects in LN, we next compared the cellular organization of spleen in mice treated in utero and throughout life with 100 µg/week of TNF-R55-Ig, LTβ-R-Ig or LFA-3-Ig. As was the case in TNF-R55-/-mice (12,27) immunohistochemical analyses of spleens from TNF-R55-Ig-treated mice showed that MAdCAM-1 expression was reduced, while expression of other marginal zone markers such as sialoadhesin and the ligands for MOMA-1 and ER-TR-9 were unaffected (Fig. 6D-F and data not shown) . In contrast, analyses of spleens from LTβ-R-Ig-treated mice showed that marginal zone markers MAdCAM-1, sialoadhesin, MOMA-1 ligand and ER-TR-9 ligand were eliminated or greatly reduced (Fig. 6G-I and data not shown). TNF-R55-Ig treatment also affected splenic lymphocyte organization as the B220 ϩ B cells failed to form discrete follicles but rather localized in a diffuse halo around the T lymphocyte-rich periarteriolar lymphoid sheaths (PALS) (Fig. 7B) . The PALS appeared intact and the overall size of the white pulp islands appeared normal. In contrast disruption of the membrane LTαβ ligand resulted in the appearance of B cells in the outer PALS, as evidenced by significant T and B cell overlap (Fig. 7C) . As both membrane LTαβ and soluble LTα/TNF ligands affected B cell positioning, both pathways may influence B cell migration within the spleen. Finally the observation that TNF-R55-Ig-treated mice had altered lymphocyte positioning while sialoadhesin, MOMA-1 and ER-TR-9 ligands were still strongly expressed suggests that there is not a direct causal relationship between the macrophage and lymphocyte effects in spleens of LTβ-R-Ig-treated mice. Whether a specific role in lymphocyte organization is indicated for MAdCAM-1 expression on endothelial cells in the splenic marginal zone remains a target of further investigation.
The roles of membrane LTαβ and soluble LTα/TNF in GC formation in response to antigen
Our results showed that LT ligand(s) influence lymphocyte positioning in secondary lymphoid organs, a process that may influence the dynamic cell reorganization which occurs during immune responses. To test for effects on immune responsiveness, 6-week-old mice which had been treated on gestational days 14 and 17 with 200 µg and weekly after birth with 100 µg of fusion protein were immunized with sheep red blood cells. Fusion protein treatment continued following immunization until 10 days after sheep red blood cells injection when the mice were sacrificed, and their spleens and parathymic LN were removed and frozen for histology. Unimmunized mice were used to control for anti-fusion protein responses. GC formation was assessed by immunohistochemistry using PNA staining. Representative results are shown in Fig. 8 . GC were either absent or present in low numbers in the spleen and parathymic LN of unimmunized, fusion protein-treated mice. In contrast, untreated and LFA-3-Ig-treated mice formed numerous PNA bright GC in spleen and parathymic (but not brachial) LN in response to sheep red blood cells priming (Table 2) . Interestingly, although there were few PNA dull GC detected in the spleen, GC formation in the parathymic LN in TNF-R55-Ig-treated animals was similar to control treated mice (Table 2 ). This result identifies distinct effects of soluble LTα/TNF antagonism in different lymphoid organs. LTβ-R-Ig-treated mice failed to form splenic GC when immunized with sheep red blood cells (Table 2) in agreement with studies on the LTα-/-and LTβ-/-mice (3,10,11). As LTβ-R-Ig-treated mice lacked parathymic LN the effect of treatment on GC formation in LN was not analyzed; however, we are currently studying the effect of LTβ-R-Ig treatment on GC formation in the mesenteric LN of animals challenged orally.
Discussion
Our results show that multiple LT ligands mediate the genesis and cellular organization of LN. Membrane LTαβ is required for the development of mandibular, brachial, axillary, parathymic, inguinal, iliac, sciatic and popliteal LN and Peyer's patches. Genesis of mesenteric, cervical, sacral and lumbar LN is LTα dependent, LTβ and TNF independent, and requires signaling independently of TNF-R55, TNF-R75 and LTβ-R. The selective function of LT ligands in LN development is supported by analyses of gene-deficient mice. The phenotype of the LTβ-R-Ig-treated mice contrasts with the phenotype of LTα-/-mice, which we confirmed lacked all of these LN, as previously reported (3, 4) . Furthermore, all of these LN were present in progeny born to TNF-R55-Ig (or LFA-3-Ig)-treated mice, consistent with the phenotype of TNF-α, TNF-R55 and TNF-R75-/-mice (5-8). Finally, LTβ-/-mice were recently reported to have cervical and mesenteric LN (10). These results suggest that there are multiple LTα-dependent pathways involved in the genesis of LN. The accumulated data (Table 1) suggest an undescribed LT pathway(s), such as an unknown protein-LTα heteromeric complex acting through a novel receptor. Alternatively, the receptor could be a novel highaffinity LTα3 receptor, capable of binding its ligand in the presence of saturating amounts of soluble competitor, as in mice treated during development with TNF-R55-Ig. Similar conclusions as to the existence of an alternative pathway for LN development were drawn from an analysis of LTβ-/-mice (10). Interestingly, some LTα-/-mice have been reported to have small numbers of LN remaining in the mesentery (4), suggesting that alternative signals, genetic backgrounds or environmental factors can induce LN genesis. Further complexities in the genesis of secondary lymphoid organs are indicated by the loss of inguinal LN in the BLR1-/-mouse (28) , and by the loss of Peyer's patches in the TNF-R55-/-mouse (22) , a phenotype that we have been unable to duplicate using TNF-R55-Ig treatment in utero.
LN which remain in LTβ-R-Ig-treated mice comprise a developmentally distinct subset that drain mucosal associated sites (23) . Neither anatomical position (mandibular and cervical, iliac and sacral) nor addressin phenotype serve to predict this developmental phenotype. These results suggest that addressin phenotype is not sufficient for characterizing LN as part of the mucosal-associated versus peripheral lymphoid system. Whether this novel set of LN mediate a particular component of mucosal immunity is under investigation.
The regulation of HEV addressin expression is not well understood, although both developmental and physiological mechanisms are involved (17, 18, 24) . Our data show that continuous LTβ-R-Ig treatment down-regulates the expression Fig. 6 . Antagonism of soluble LTα/TNF disrupts expression of MAdCAM-1, but not macrophage markers, in spleen. Spleens were taken from 6-week-old mice which had been treated in utero on gestational days 14 and 17 with 200 µg, and weekly after birth with 100 µg, of LFA-3-Ig (A, B and C), TNF-R55-Ig (D, E and F) or LTβ-R-Ig (G, H and I). Spleen samples were stained with mAb specific for MAdCAM-1 (MECA367; A, D and G), marginal zone macrophages (ER-TR-9; B, E and H) and metallophilic macrophages (anti-sialoadhesin; C, F and I). Magnification ϫ50.
of addressins in both of the sets of LN defined herein. Such regulation of LN addressin expression appears to be mediated by activated lymphocytes, the only cell type shown to express LTαβ (1). Less marked down-regulation of addressin levels was reported in adult mice treated with LTβ-R-Ig (26), suggesting that multiple factors may regulate addressin expression. MAdCAM-1 expression is unaltered in LN of mice treated with TNF-R55-Ig, although it is eliminated in the spleens of the same animals. These results identify an important functional difference between the soluble LTα/TNF homotrimers and the membrane LTαβ heterotrimer, and demonstrate distinct effects of the these ligands in different lymphoid compartments. The observation that MAdCAM-1 is expressed on all LN early during embryonic development (24) suggests a dynamic interplay between membrane LTαβ expressed by early infiltrating lymphoid cells and LTβ-R ϩ endothelial cells to upregulate MAdCAM-1 expression and facilitate the recruitment of additional lymphocytes to the site of LN development. Such a scenario would be consistent with the expression of LTβ-R early during embryogenesis (29) . Potential interplay of membrane LTαβ and MAdCAM-1 expression is also suggested by the phenotype of transgenic mice in which the expression of LTα, but not TNF, in pancreatic islets and kidney induced expression of MAdCAM-1 and the development of LN (30) . It is plausible that MAdCAM-1 expression was a direct consequence of the expression of LTαβ on the membrane of islet and kidney cells. On the other hand, a recent report showed that in utero treatment with anti-MAdCAM-1 mAb did not abrogate LN development in the resulting progeny (24) . Finally, our unpublished results obtained using LN tissue from neonates born to LTβ-R-Ig-treated pregnant mice showed marked down-regulation of MAdCAM-1 expression in mesenteric LN. Together these data suggest that MAdCAM-1 expression is not required for LN genesis.
LN of LTβ-R-Ig-treated mice contained both T and B cells, despite the down-regulation of addressin expression. Lymphocytes and other cells gain access to the LN cortex not only via addressin ϩ HEV but also via the afferent lymphatic vessels which spill into the subcapsular sinus. Blockade of membrane LTαβ induced a significant loss of sialoadhesin expression on macrophages in the subcapsular sinus of LN, similar to the MOMA-1 phenotype reported in mesenteric LN of LTβ-/-mice (10). Blockade of soluble LTα/TNF had no effect on LN sialoadhesin or addressin expression. In contrast antagonism of soluble LTα/TNF and membrane LTαβ induced similar changes in LN lymphocyte organization, such that B cells appeared within the LN subcapsular sinus. Thus the normal expression of addressins and of functional markers in the LN subcapsular sinus is not sufficient to direct normal B lymphocyte positioning in the LN.
A role for the splenic marginal zone in lymphocyte trafficking similar to that of LN HEV has been proposed (31) and marginal zone macrophages were hypothesized to regulate this function (32) . We and others have shown that cells within the splenic marginal zone fail to express defined surface antigens when LT is disrupted (3, (9) (10) (11) (12) 26) . In the spleen soluble LTα/TNF blockade leads to the dissolution of discrete splenic lymphoid follicles, causing B cells to form a continuous ring around the T cell occupied PALS (3, 5, 12) . This phenotype appears to be due primarily to disruption of TNF signaling, as it is similar to phenotypes described in both TNF-R55-/-and TNF-/-mice (5, 12, 32) , and may have a developmental basis, as chronic treatment of adult mice with TNF-R55-Ig did not cause the same disruption (26) . Membrane LTαβ blockade leads to a similar loss of polarized B cell follicles, except that the B cells appear to be located in the outer PALS. It seems likely that one aspect of membrane LT and TNF function is to control distinct steps in B cell migration within lymphoid organs. In this respect the similarity of the splenic B cell disorganization in the TNF-/-and TNF-R55-/-mice to that described in the chemokine receptor BLR1-/-mouse (26) is noteworthy. Whether splenic B cell migration is mediated by cells within the splenic marginal zone Six-week-old mice were dosed with 200 µg fusion protein on days 14 and 17 during gestation and with 100 µg/week after birth. An additional treatment with PBS or fusion protein was administered 1 week after the immunization with 250 µl 20% sheep red blood cells in PBS i.p. Mice were sacrificed 10 days after immunization. Spleen and parathymic LN were examined for PNA reactivity by immunohistochemistry. Each group contained two to four animals.
a The percentage of PNA ϩ follicles was determined from a count of at least 30 follicles of spleen and at least eight follicles of parathymic LN per animal.
b ND, not determined; these animals lack parathymic LN.
is not yet known. Regardless, the disruption of lymphocyte organization has marked functional consequences since LTβ-R-Ig-and TNF-R55-Ig-treated mice do not form splenic GC following antigenic stimulation (Table 2) . This is consistent with the results of previous analyses of GC formation in mice deficient in LT/TNF components (5, (10) (11) (12) (13) 33) . Interestingly, we have shown that GC formation in the parathymic LN of TNF-R55-Ig-treated mice in response to sheep red blood cells challenge appeared normal suggesting that there may be different requirements for GC formation in spleen and LN. Consistent with this hypothesis, GC were reported in mesenteric LN but not spleen of LTβ-/-mice (10). Finally, antagonism of the TNF pathway in the adult mouse using TNF-R55-Ig failed to disrupt GC formation in the spleen, suggesting that TNF-/-and TNF-R55-/-mice have an additional developmental component to their phenotypes (26) . Our results suggest that lymphocyte ligands such as membrane LTαβ and TNF play a critical role in communicating signals to maintain or influence the cellular organization of the secondary lymphoid organs. In particular, membrane LTαβ and TNF may provide critical signals for B cell organization within the follicles of both the spleen and LN. Such roles are similar to those played by other members of the TNF family, including CD40L, which signals its receptor to influence the viability of B lymphocytes and their formation of secondary follicles in response to antigen (34) , and OX40L, which influences the development of PALS-associated B cell foci (35) . Thus, LT/TNF family members may comprise a molecular communication network which positions cells within lymphoid organs to allow efficient immune responses.
